Response to Comment on "Epigenetic activation of the drug transporter OCT2 sensitizes renal cell carcinoma to oxaliplatin"

Affiliations

• ¹ Institute of Drug and Pharmaceutical Analysis, Zhejiang Province Key Laboratory of Anti-Cancer Drug Research, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou 310058, China.
• ² Department of Urology, Cancer Hospital of Zhejiang Province, Hangzhou 310022, China.
• ³ Department of Urology, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou 310003, China.
• ⁴ Institute of Drug and Pharmaceutical Analysis, Zhejiang Province Key Laboratory of Anti-Cancer Drug Research, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou 310058, China. zengsu@zju.edu.cn yuls@zju.edu.cn.